

Gary A Ulaner

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6201299/gary-a-ulaner-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

116
papers

3,487
citations

32
h-index

56
g-index

125
ext. papers

4,402
ext. citations

6.9
avg, IF

5.38
L-index

#	Paper	IF	Citations
116	Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102029	2.2	3
115	¹⁶ E ¹⁸ F-fluoro- ¹⁷ EFluoroestradiol (FES): Clinical Applications for Patients With Breast Cancer.. <i>Seminars in Nuclear Medicine</i> , 2022 ,	5.4	3
114	Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 6-14	8.9	3
113	Diffusion and Perfusion MRI Predicts Response Preceding and Shortly After Radiosurgery to Brain Metastases: A Pilot Study. <i>Journal of Neuroimaging</i> , 2021 , 31, 317-323	2.8	4
112	Intra-arterial Melphalan for Neurologic Non-Langerhans Cell Histiocytosis. <i>Neurology</i> , 2021 , 96, 1091-1095	3.5	1
111	Evidence-Based Best Practices: ¹⁸ F-FDG PET Staging of Newly Diagnosed Breast Cancer. <i>Clinical Nuclear Medicine</i> , 2021 , 46, 569-570	1.7	3
110	Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity. <i>Blood Reviews</i> , 2021 , 46, 100732	11.1	9
109	Head-to-Head Evaluation of F-FES and F-FDG PET/CT in Metastatic Invasive Lobular Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 326-331	8.9	15
108	Clinical Utility of F-FDG PET/CT for Staging and Treatment Planning in Urachal Adenocarcinoma. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 643-647	8.9	1
107	F-FDG PET/CT versus anatomic imaging for evaluating disease extent and clinical trial eligibility in Erdheim-Chester disease: results from 50 patients in a registry study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 1154-1165	8.8	0
106	Improved image reconstruction of Zr-immunoPET studies using a Bayesian penalized likelihood reconstruction algorithm. <i>EJNMMI Physics</i> , 2021 , 8, 6	4.4	3
105	Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 1278-1284	8.9	7
104	CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody. <i>Journal of Nuclear Medicine</i> , 2021 ,	8.9	6
103	Malignant perivascular epithelioid cell tumor of the ileum on F-fluorodeoxyglucose positron emission tomography/ computed tomography with pathological correlation. <i>World Journal of Nuclear Medicine</i> , 2021 , 20, 208-210	0.6	
102	The Contribution of MicroRNAs to the Inflammatory and Neoplastic Characteristics of Erdheim-Chester Disease. <i>Cancers</i> , 2020 , 12,	6.6	1
101	Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted Zr-Pertuzumab PET/CT. <i>Radiology</i> , 2020 , 296, 370-378	20.5	13
100	Rosai-Dorfman Disease-Utility of ¹⁸ F-FDG PET/CT for Initial Evaluation and Follow-up. <i>Clinical Nuclear Medicine</i> , 2020 , 45, e260-e266	1.7	8

99	The Influence of Glycans-Specific Bioconjugation on the FcRI Binding and Performance of Zr-DFO-Pertuzumab. <i>Theranostics</i> , 2020 , 10, 1746-1757	12.1	15
98	Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders. <i>Best Practice and Research in Clinical Haematology</i> , 2020 , 33, 101148	4.2	4
97	Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series. <i>Neuro-Oncology</i> , 2020 , 22, 979-992	1	13
96	Efficacy and Determinants of Response to HER Kinase Inhibition in -Mutant Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2020 , 10, 198-213	24.4	41
95	Mucinous urachal adenocarcinoma: A potential nonfluorodeoxyglucose-avid pitfall on fluorine-fluorodeoxyglucose positron emission tomography/computed tomography. <i>World Journal of Nuclear Medicine</i> , 2020 , 19, 432-434	0.6	1
94	Acute Aortic Dissection Initially Suspected on 18F-FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2020 , 45, 819-829		
93	Extramedullary Myeloma of the Uterus on 18F-FDG PET/CT: A Rare Manifestation of Multiple Myeloma. <i>Clinical Nuclear Medicine</i> , 2020 , 45, 873-875	1.7	1
92	Accelerated single cell seeding in relapsed multiple myeloma. <i>Nature Communications</i> , 2020 , 11, 3617	17.4	16
91	CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging. <i>Radiology</i> , 2020 , 295, 606-615	20.5	35
90	HER2-Mediated Internalization of Cytotoxic Agents in Amplified or Mutant Lung Cancers. <i>Cancer Discovery</i> , 2020 , 10, 674-687	24.4	66
89	Skeleton on FDG PET/CT 2019 , 9-32		
88	Lymph Nodes on FDG PET/CT 2019 , 211-223		
87	Spleen on FDG PET/CT 2019 , 127-131		
86	PET/CT for Patients With Breast Cancer: Where Is the Clinical Impact?. <i>American Journal of Roentgenology</i> , 2019 , 213, 254-265	5.4	31
85	Efficacy of MEK inhibition in patients with histiocytic neoplasms. <i>Nature</i> , 2019 , 567, 521-524	50.4	126
84	ACR Appropriateness Criteria□ Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women. <i>Journal of the American College of Radiology</i> , 2019 , 16, S428-S439	3.5	7
83	Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib. <i>Clinical Cancer Research</i> , 2019 , 25, 7381-7387	12.9	9
82	Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial. <i>JAMA Network Open</i> , 2019 , 2, e1916211	10.4	5

81	Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. <i>Nature Medicine</i> , 2019 , 25, 1839-1842	50.5	55
80	Hepatocellular Carcinoma Mimicking Neuroendocrine Tumor Metastasis on 68Ga-DOTATATE PET/CT. <i>Clinical Nuclear Medicine</i> , 2019 , 44, 330-331	1.7	3
79	Patient Repositioning Reveals a Malignant Pleura Effusion Initially Mistaken as a Bone Metastasis on 18FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2019 , 44, 969-970	1.7	1
78	Focal Immunotherapy-Induced Pancreatitis Mimicking Metastasis on FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2019 , 44, 836-837	1.7	12
77	Factors Affecting Oncologic Outcomes of 90Y Radioembolization of Heavily Pre-Treated Patients With Colon Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2019 , 18, 8-18	3.8	21
76	F-FDG PET/CT for Systemic Staging of Newly Diagnosed Breast Cancer in Men. <i>Journal of Nuclear Medicine</i> , 2019 , 60, 472-477	8.9	5
75	Detection of recurrent pancreatic cancer: value of second-opinion interpretations of cross-sectional images by subspecialized radiologists. <i>Abdominal Radiology</i> , 2019 , 44, 586-592	3	5
74	Single-agent dabrafenib for -mutated histiocytosis. <i>Haematologica</i> , 2018 , 103, e177-e180	6.6	29
73	Trends in oncologic hybrid imaging. <i>European Journal of Hybrid Imaging</i> , 2018 , 2, 1	1.7	15
72	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. <i>Nature</i> , 2018 , 554, 189-194	50.4	388
71	Molecular Classification of Breast Cancer. <i>PET Clinics</i> , 2018 , 13, 325-338	2.2	48
70	Adalimumab-Induced Epstein-Barr Virus-Related Lymphoproliferative Disorder on FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2018 , 43, 344-345	1.7	0
69	Long-Half-Life Zr-Labeled Radiotracers Can Guide Percutaneous Biopsy Within the PET/CT Suite Without Reinjection of Radiotracer. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 399-402	8.9	8
68	Diagnostic Role of Fluorodeoxyglucose PET in Breast Cancer: A History to Current Application. <i>PET Clinics</i> , 2018 , 13, 355-361	2.2	9
67	Mazabraud's Syndrome Mimicking Metastases on FDG PET/CT in a Patient With Colon Cancer. <i>Clinical Nuclear Medicine</i> , 2018 , 43, 625-626	1.7	3
66	Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. <i>JAMA Oncology</i> , 2018 , 4, 384-388	13.4	191
65	First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 900-906	8.9	82
64	Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2532-2537	2.2	217

63	ACR Appropriateness Criteria Evaluation of the Symptomatic Male Breast. <i>Journal of the American College of Radiology</i> , 2018 , 15, S313-S320	3.5	21
62	Amino Acid Metabolism as a Target for Breast Cancer Imaging. <i>PET Clinics</i> , 2018 , 13, 437-444	2.2	10
61	Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer. <i>PET Clinics</i> , 2018 , 13, 423-435	2.2	15
60	Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 1428-1437	8.8	41
59	F-FDG-PET/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 1420-1427	8.8	23
58	FDG PET/CT Assesses the Risk of Femoral Pathological Fractures in Patients With Metastatic Breast Cancer. <i>Clinical Nuclear Medicine</i> , 2017 , 42, 264-270	1.7	12
57	Human Epidermal Growth Factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer: Noninvasive Measurement of a Biomarker Integral to Tumor Treatment and Prognosis. <i>PET Clinics</i> , 2017 , 12, 269-288	2.2	36
56	Pathologically Benign Lymph Nodes Can Mimic Malignancy on Imaging in Patients With Angiomatoid Fibrous Histiocytoma. <i>Clinical Orthopaedics and Related Research</i> , 2017 , 475, 2274-2279	2.2	4
55	F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials. <i>Clinical Cancer Research</i> , 2017 , 23, 3053-3060	12.9	45
54	David Versus the Goliaths for the Detection of Bone Metastases. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 1776-1777	8.9	3
53	⁸⁹ Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. <i>Clinical Nuclear Medicine</i> , 2017 , 42, 912-917	1.7	54
52	Value of second-opinion review of outside institution PET-CT examinations. <i>Nuclear Medicine Communications</i> , 2017 , 38, 306-311	1.6	10
51	Transient Osteoporosis of the Hip on FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2017 , 42, 401-402	1.7	
50	High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. <i>Blood</i> , 2017 , 130, 1007-1013	2.2	69
49	Prospective Clinical Trial of F-Fluciclovine PET/CT for Determining the Response to Neoadjuvant Therapy in Invasive Ductal and Invasive Lobular Breast Cancers. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 1037-1042	8.9	34
48	Specialized second-opinion radiology review of PET/CT examinations for patients with diffuse large B-cell lymphoma impacts patient care and management. <i>Medicine (United States)</i> , 2017 , 96, e9411	1.8	3
47	"Comment on Hatzoglou et al.: Dynamic contrast-enhanced MRI perfusion vs ¹⁸ F-FDG PET/CT in differentiating brain tumor progression from radiation injury"-Reply. <i>Neuro-Oncology</i> , 2017 , 19, 301-302 ¹		
46	Unilateral Suppression of Brown Fat on FDG PET/CT in Horner Syndrome. <i>Clinical Nuclear Medicine</i> , 2016 , 41, 797-8	1.7	2

45	FDG-Avid Intrathecal Inflammation Following Administration of Intrathecal Methotrexate. <i>Clinical Nuclear Medicine</i> , 2016 , 41, 995-997	1.7	1
44	The Impact That Number of Analyzed Metastatic Breast Cancer Lesions Has on Response Assessment by 18F-FDG PET/CT Using PERCIST. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 1102-4	8.9	19
43	A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation. <i>Neuro-Oncology</i> , 2016 , 18, 873-80	1	51
42	Molecular Imaging of Biomarkers in Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2016 , 57 Suppl 1, 53S-9S	8.9	44
41	Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 1350-6	8.9	43
40	Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket Study. <i>Blood</i> , 2016 , 128, 480-480	2.2	3
39	Prognostic value of FDG PET/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 6, 120-7	2.2	26
38	(18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 43, 1937-44	8.8	31
37	Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0. <i>European Journal of Radiology</i> , 2016 , 85, 1224-31	4.7	33
36	Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 1523-1528	8.9	118
35	Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015 , 42, 1666-1673	8.8	50
34	Detection of Internal Mammary Adenopathy in Patients With Breast Cancer by PET/CT and MRI. <i>American Journal of Roentgenology</i> , 2015 , 205, 899-904	5.4	23
33	Reply: Breast Cancer Staging: To Which Women Should 18F-FDG PET/CT Be Offered?. <i>Journal of Nuclear Medicine</i> , 2015 , 56, 1293-4	8.9	3
32	Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma. <i>Journal of Nuclear Medicine</i> , 2015 , 56, 1674-80	8.9	52
31	Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma. <i>Radiology</i> , 2015 , 277, 518-26	20.5	16
30	Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. <i>Blood</i> , 2015 , 125, 2579-81	2.2	81
29	FDG-PET/CT versus contrast enhanced CT for prediction of progression-free and disease-specific survival in stage IV breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1051-1051	2.2	2
28	Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 1578-83	8.9	68

27	False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma. <i>Journal of Clinical Oncology</i> , 2014 , 32, 51-6	2.2	21
26	Is methylene diphosphonate bone scan necessary for initial staging of Ewing sarcoma if 18F-FDG PET/CT is performed?. <i>American Journal of Roentgenology</i> , 2014 , 202, 859-67	5.4	20
25	FDG PET/CT findings in a rare case of giant fibrovascular polyp of the esophagus harboring atypical lipomatous tumor/well-differentiated liposarcoma. <i>Clinical Nuclear Medicine</i> , 2014 , 39, 288-91	1.7	6
24	Musculoskeletal tumors and tumor-like conditions: common and avoidable pitfalls at imaging in patients with known or suspected cancer: Part A: benign conditions that may mimic malignancy. <i>International Orthopaedics</i> , 2013 , 37, 871-6	3.8	8
23	Musculoskeletal tumours and tumour-like conditions: common and avoidable pitfalls at imaging in patients with known or suspected cancer: Part B: malignant mimics of benign tumours. <i>International Orthopaedics</i> , 2013 , 37, 877-82	3.8	7
22	Comparison of the effectiveness of MRI perfusion and fluorine-18 FDG PET-CT for differentiating radiation injury from viable brain tumor: a preliminary retrospective analysis with pathologic correlation in all patients. <i>Clinical Imaging</i> , 2013 , 37, 451-7	2.7	26
21	Identifying and distinguishing treatment effects and complications from malignancy at FDG PET/CT. <i>Radiographics</i> , 2013 , 33, 1817-34	5.4	57
20	FDG-avid venous malformation could mimic malignancy on 18F-FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2013 , 38, 826-8	1.7	1
19	Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer. <i>Cancer Medicine</i> , 2013 , 2, 725-33	4.8	40
18	Hill-Sachs lesion on FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2013 , 38, 65-6	1.7	
17	Focused regional FDG PET/CT detects more osseous metastases than does whole-body PET/CT. <i>Clinical Nuclear Medicine</i> , 2013 , 38, 217-8	1.7	
16	Breast implant foreign body reaction mimicking breast cancer recurrence on FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2013 , 38, 480-1	1.7	12
15	Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. <i>Cancer</i> , 2012 , 118, 5454-62	6.4	48
14	False-positive FDG PET/CT due to liver parenchymal injury caused by a surgical retractor. <i>Clinical Nuclear Medicine</i> , 2012 , 37, 910-1	1.7	7
13	Ipilimumab-induced colitis on FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2012 , 37, 629-30	1.7	23
12	FDG PET/CT demonstration of right atrium metastasis overlooked on contrast-enhanced CT. <i>Clinical Nuclear Medicine</i> , 2011 , 36, 405-6	1.7	5
11	B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy--initial experience. <i>Radiology</i> , 2008 , 246, 895-902	20.5	27
10	An unsuspected MR projectile: a "wooden" chair with metal bracing. <i>Journal of Magnetic Resonance Imaging</i> , 2006 , 23, 781-2	5.6	2

9	Visualization of telomerase reverse transcriptase (hTERT) promoter activity using a trimodality fusion reporter construct. <i>Journal of Nuclear Medicine</i> , 2006 , 47, 270-7	8.9	12
8	IVF results in de novo DNA methylation and histone methylation at an Igf2-H19 imprinting epigenetic switch. <i>Molecular Human Reproduction</i> , 2005 , 11, 631-40	4.4	151
7	Activating and silencing histone modifications form independent allelic switch regions in the imprinted Gnas gene. <i>Human Molecular Genetics</i> , 2004 , 13, 741-50	5.6	21
6	Epigenetic regulation of the taxol resistance-associated gene TRAG-3 in human tumors. <i>Cancer Genetics and Cytogenetics</i> , 2004 , 151, 1-13		27
5	Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas. <i>Genes Chromosomes and Cancer</i> , 2004 , 41, 155-62	5	78
4	Telomere maintenance in clinical medicine. <i>American Journal of Medicine</i> , 2004 , 117, 262-9	2.4	21
3	Epigenetic regulation of Igf2/H19 imprinting at CTCF insulator binding sites. <i>Journal of Cellular Biochemistry</i> , 2003 , 90, 1038-55	4.7	32
2	Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. <i>Human Molecular Genetics</i> , 2003 , 12, 535-49	5.6	112
1	Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. <i>Cancer Research</i> , 2003 , 63, 1759-63	10.1	118